Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
04 2021
Historique:
received: 14 10 2020
revised: 10 12 2020
accepted: 08 01 2021
pubmed: 28 1 2021
medline: 11 1 2022
entrez: 27 1 2021
Statut: ppublish

Résumé

Men engaged in high physical activity have lower risks of advanced and fatal prostate cancer. Mechanisms underlying this association are not well understood but may include systemic and tumor-specific effects. We investigated potential mechanisms linking physical activity and gene expression in prostate tissue from men with prostate cancer. We included a subset of 118 men in the Health Professionals Follow-up Study diagnosed with prostate cancer between 1986 and 2005 with whole-transcriptome gene expression profiling on tumor and adjacent normal prostate tissue and physical activity data. Long-term vigorous physical activity was self-reported as the average time spent engaged in various forms of recreational physical activity at baseline and biennially until prostate cancer diagnosis. Gene set enrichment analysis was performed among KEGG and Hallmark gene sets to identify pathways with differential expression based on vigorous physical activity. In adjacent normal tissue, we identified 25 KEGG gene sets enriched (downregulated) in the highest compared with lowest quintile of vigorous physical activity at an FDR <0.10, including a number of cancer- and immune-related pathways. Although no gene sets reached statistical significance in tumor tissue, top gene sets differentially expressed included TGF beta, apoptosis, and p53 signaling pathways. These findings suggest that physical activity may influence the tumor microenvironment. Future studies are needed to confirm these findings and further investigate potential mechanisms linking physical activity to lethal prostate cancer. Identification of gene expression alterations in the prostate associated with physical activity can improve our understanding of prostate cancer etiology.

Sections du résumé

BACKGROUND
Men engaged in high physical activity have lower risks of advanced and fatal prostate cancer. Mechanisms underlying this association are not well understood but may include systemic and tumor-specific effects. We investigated potential mechanisms linking physical activity and gene expression in prostate tissue from men with prostate cancer.
METHODS
We included a subset of 118 men in the Health Professionals Follow-up Study diagnosed with prostate cancer between 1986 and 2005 with whole-transcriptome gene expression profiling on tumor and adjacent normal prostate tissue and physical activity data. Long-term vigorous physical activity was self-reported as the average time spent engaged in various forms of recreational physical activity at baseline and biennially until prostate cancer diagnosis. Gene set enrichment analysis was performed among KEGG and Hallmark gene sets to identify pathways with differential expression based on vigorous physical activity.
RESULTS
In adjacent normal tissue, we identified 25 KEGG gene sets enriched (downregulated) in the highest compared with lowest quintile of vigorous physical activity at an FDR <0.10, including a number of cancer- and immune-related pathways. Although no gene sets reached statistical significance in tumor tissue, top gene sets differentially expressed included TGF beta, apoptosis, and p53 signaling pathways.
CONCLUSIONS
These findings suggest that physical activity may influence the tumor microenvironment. Future studies are needed to confirm these findings and further investigate potential mechanisms linking physical activity to lethal prostate cancer.
IMPACT
Identification of gene expression alterations in the prostate associated with physical activity can improve our understanding of prostate cancer etiology.

Identifiants

pubmed: 33500320
pii: 1055-9965.EPI-20-1461
doi: 10.1158/1055-9965.EPI-20-1461
pmc: PMC8132456
mid: NIHMS1667178
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-756

Subventions

Organisme : NCI NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NIEHS NIH HHS
ID : T32 ES007069
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009001
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136578
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA113913
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA174206
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):258-264
pubmed: 30464020
Br J Cancer. 2011 Mar 15;104(6):971-81
pubmed: 21407225
BMC Genomics. 2017 Nov 14;18(Suppl 8):802
pubmed: 29143608
Prostate. 2003 Aug 1;56(3):201-6
pubmed: 12772189
Eur Urol. 2019 Jul;76(1):33-40
pubmed: 30301696
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
JAMA Intern Med. 2016 Jun 1;176(6):816-25
pubmed: 27183032
Eur Urol. 2011 Nov;60(5):1029-44
pubmed: 21802197
J Mol Diagn. 2015 Jul;17(4):374-81
pubmed: 25937617
Epidemiology. 1996 Jan;7(1):81-6
pubmed: 8664406
Nat Rev Cancer. 2013 Jul;13(7):497-510
pubmed: 23760024
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-60
pubmed: 25371445
Med Sci Sports Exerc. 2011 Aug;43(8):1575-81
pubmed: 21681120
Clin Cancer Res. 2016 Feb 1;22(3):765-772
pubmed: 26490316
Br J Cancer. 2011 Jun 7;104(12):1920-8
pubmed: 21559022
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):57-64
pubmed: 25527697
Cancer Causes Control. 2014 Apr;25(4):515-23
pubmed: 24504435
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Nat Rev Cancer. 2008 Mar;8(3):205-11
pubmed: 18235448
Nat Rev Cancer. 2017 Sep 25;17(10):620-632
pubmed: 28943640
Nucleic Acids Res. 2003 Feb 15;31(4):e15
pubmed: 12582260
Arch Intern Med. 2005 May 9;165(9):1005-10
pubmed: 15883238
Endocr Relat Cancer. 2013 May 20;20(3):R83-99
pubmed: 23456430
J Appl Physiol (1985). 2004 Feb;96(2):450-4
pubmed: 14715676
J Clin Oncol. 2011 Dec 10;29(35):4620-6
pubmed: 22067406
Cancer Res. 2011 Jun 1;71(11):3889-95
pubmed: 21610110
J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26
pubmed: 8757191

Auteurs

Claire H Pernar (CH)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. cpernar@mail.harvard.edu.

Giovanni Parmigiani (G)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Edward L Giovannucci (EL)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Eric B Rimm (EB)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Svitlana Tyekucheva (S)

Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Massimo Loda (M)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Stephen P Finn (SP)

Department of Histopathology, Trinity College, Dublin, Ireland.
Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Matthew G Vander Heiden (MG)

Koch Institute for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Michelangelo Fiorentino (M)

Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pathology Unit, Addarii Institute, S. Orsola-Malpighi Hospital, Bologna, Italy.

Ericka M Ebot (EM)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

Lorelei A Mucci (LA)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH